| Literature DB >> 24979544 |
Craig L Leonardi1, Kenneth B Gordon2.
Abstract
This article discusses the scientific rationale for the use of cytokine inhibitors, including ustekinumab, an inhibitor of the interleukin (IL)-12 and IL-23 pathways in psoriasis. Also addressed are the efficacy and safety data for this agent, as well as for several emerging therapies that target other cytokine pathways in psoriasis: the IL-17 inhibitors secukinumab, ixekizumab, and brodalumab, the IL-23 blocker tildrakizumab, and the small-molecule kinase inhibitors apremilast (a phosphodiesterase-4 blocker) and tofacitinib (a Janus kinase inhibitor). 2014 published by Frontline Medical Communications.Entities:
Keywords: Apremilast; JAK; Janus kinase inhibitors; brodalumab; interleukin-12/23 inhibitors; interleukin-17 inhibitors; ixekizumab; phosphodiesterase-4 inhibitors; psoriasis treatment; secukinumab; tildrakizumab; tofacitinib; tumor necrosis factor inhibitors; ustekinumab
Mesh：
Substances：
Year: 2014 PMID： 24979544 DOI： 10.12788/j.sder.0066
Source DB: PubMed Journal: Semin Cutan Med Surg ISSN： 1085-5629